key: cord-0881097-k3rqbg5e
authors: Schroeder, Lee F; Bachman, Michael A; Idoni, Allison; Gegenheimer-Holmes, Jennifer; Kronick, Steven L; Valdez, Riccardo; Lephart, Paul R
title: Predicting Direct-Specimen SARS-CoV-2 Assay Performance Using Residual Patient Samples
date: 2021-11-10
journal: J Appl Lab Med
DOI: 10.1093/jalm/jfab159
sha: 1821955379ab4c5be667f731950b7b18de544e00
doc_id: 881097
cord_uid: k3rqbg5e

BACKGROUND: Diagnostic sensitivities of point-of-care SARS-CoV-2 assays depend on specimen type and population-specific viral loads. Evaluation of these assays require ‘direct’ specimens from paired-swab studies rather than more accessible residual specimens in viral transport media (VTM). METHODS: Residual VTM and limit-of-detection studies were conducted on Abbott ID NOW™ COVID-19, Quidel Sofia 2™ SARS Antigen FIA, and DiaSorin Simplexa™ COVID-19 Direct assays, with cycle threshold (CT) adjustments to approximate direct-specimen testing based on gene-target doubling each PCR cycle. Logistic regression was used to model assay performance by specimen CT. These models were applied to CT distributions of symptomatic and asymptomatic populations presenting to emergency services to predict the percent of specimens that would be detected by each assay. A 96-sample paired-swab study was conducted to confirm model results. RESULTS: When using direct nasopharyngeal samples and fit with either VTM or limit-of-detection data, percent positivities for ID NOW (symptomatic 94.9%/97.4%; asymptomatic 88.4.0%/89.6%) and Simplexa (symptomatic 97.8%/97.2%; asymptomatic 91.1%/90.8%) were predicted to be similar. Likewise, fit with VTM data, percent positivities for ID NOW with direct nasal specimens (symptomatic 77.8%; asymptomatic 64.5%) and Sofia 2 with direct nasopharyngeal specimens (symptomatic 76.6%, asymptomatic 60.3%) were similar. The paired-swab study comparing direct nasopharyngeal specimens on ID NOW and nasopharyngeal VTM specimens on Simplexa showed 99% concordance. CONCLUSIONS: Assay performance can be modeled as dependent on viral load, fit using laboratory bench study results, and adjusted to account for direct-specimen testing. When using nasopharyngeal specimens, direct testing on Abbott ID NOW and VTM testing on DiaSorin Simplexa have similar performance.

Background 52

Diagnostic sensitivities of point-of-care SARS-CoV-2 assays depend on specimen type and 53

population-specific viral loads. Evaluation of these assays require 'direct' specimens from 54 paired-swab studies rather than more accessible residual specimens in viral transport media 55

(VTM). 56 57 Methods 58

Residual VTM and limit-of-detection studies were conducted on Abbott ID NOW™ COVID-19, 59

Quidel Sofia 2™ SARS Antigen FIA, and DiaSorin Simplexa™ COVID-19 Direct assays, with 60 cycle threshold (CT) adjustments to approximate direct-specimen testing based on gene-target 61

doubling each PCR cycle. Logistic regression was used to model assay performance by 62 specimen CT. These models were applied to CT distributions of symptomatic and asymptomatic 63

populations presenting to emergency services to predict the percent of specimens that would be 64 detected by each assay. A 96-sample paired-swab study was conducted to confirm model 65 results.

Results 68

When using direct nasopharyngeal samples and fit with either VTM or limit-of-detection data, 69

percent positivities for ID NOW (symptomatic 94.9%/97.4%; asymptomatic 88.4.0%/89.6%) and 70

Simplexa (symptomatic 97.8%/97.2%; asymptomatic 91.1%/90.8%) were predicted to be 71 similar. Likewise, fit with VTM data, percent positivities for ID NOW with direct nasal specimens 72 (symptomatic 77.8%; asymptomatic 64.5%) and Sofia 2 with direct nasopharyngeal specimens 73 (symptomatic 76.6%, asymptomatic 60.3%) were similar. The paired-swab study comparing 74 direct nasopharyngeal specimens on ID NOW and nasopharyngeal VTM specimens on 75

Simplexa showed 99% concordance. 76 77

Conclusions 78

Assay performance can be modeled as dependent on viral load, fit using laboratory bench study 79 results, and adjusted to account for direct-specimen testing. When using nasopharyngeal 80 specimens, direct testing on Abbott ID NOW and VTM testing on DiaSorin Simplexa have 81 similar performance. 82 83 84

Impact statement 85

Throughout the COVID-19 pandemic, there has been a proliferation of SARS-CoV-2 assays 86

with Emergency Use Approval. There is significant variation in the analytic sensitivities of these 87 diagnostics as well as a strong dependence of diagnostic sensitivity on patient population and 88 specimen type, making it difficult for institutions to evaluate tests for implementation. 89

Furthermore, many point-of-care tests require direct-specimens, rather than residual viral 90 transport media, presenting additional challenges for verification. This study demonstrates a 91 model that can use data from limit-of-detection and residual viral transport media studies to 92

predict the performance of direct-specimen assays in different patient populations. 93 3 94

Introduction 95 96

SARS-CoV-2 diagnostic testing throughout much of the pandemic has been defined by reagent 97 scarcity and testing delays.

(1-4) Nonetheless, there has been a proliferation of assay options 98 on the market, from central laboratory instruments to near-patient and point-of-care formats, 99

including multiple specimen types, and both nucleic acid as well as antigen targets.(5,6) 100

Importantly, the accuracy of these assays varies substantially according to viral RNA 101 concentration in samples, with a strong dependence on specimen type and patient 102

population.(7-10) While the availability of numerous assays and specimen types is desirable, 103 verification of assay accuracy with different specimen types in different patient populations is 104

challenging. When assays are approved for use with viral transport media (VTM), verification is 105 straight-forward, as residual samples can be used. However, many point-of-care assays require 106 'direct' or 'dry' swabs, where swabs are placed directly into assay reagents without first diluting 107

in VTM. For these assays, verification requires paired-swab studies, where two swabs are 108 collected from each patient, one for the index and one for the reference test. Paired-swab 109 designs, however, are time-consuming and difficult to conduct when positivity is low.

Considering the large set of assay-, specimen type-, and patient population-combinations that 111

an institution must consider, paired-swab designs as the initial evaluation are often untenable.

The goal of this study was to identify a rapid point- The underlying assumption of this model is that specimen viral load is the primary determinant 133

of SARS-CoV-2 assay diagnostic sensitivities, whether it be nucleic acid testing or antigen 134

testing. In turn, PCR cycle threshold (CT) is assumed to be an estimator of viral load. The 135

higher the viral load, the lower the CT will be in PCR assays that detect SARS-CoV-2, and the 136 more likely any assay will detect virus in that sample. By using CT distributions of positive cases 137 in different patient populations, one can estimate the performance expected for various assays 138

in use, and potentially to be used, in a health system. This performance measure is calculated 139 by mapping CT-specific analytic sensitivities to the CT distribution of the population-of-interest. 140 Development of the model followed five steps: 141 142

Step 1: The model assumes negligible CT-bias between assays used to generate analytic 143 sensitivity curves and the population-specific CT distributions. Accordingly, assay CTs were 144 compared for bias with residual VTM samples (Table 1 , #1 and #2).

Step 2: Data from multiple sources were used to fit models of CT-specific analytic sensitivity. 147

Positive cases from a study conducted in April, 2020(7) were used for ID NOW and Simplexa 148 characterization. Briefly, twenty-four foam nasal swabs were tested directly with ID NOW (Table  149 1, #3), and the paired nasopharyngeal VTM samples were tested on central laboratory assay 150 (see below) as well as ID NOW ( (detection/no detection) was compared to CTs of these same specimens derived from either the 159

Abbott RealTime m2000™ SARS-CoV-2 assay (April, 2020 study) or Abbot Alinity™ m SARS-160

COV-2 assay (Abbott Molecular, Des Plaines, IL; Table 1 ). All m2000 CTs were increased by 10 161 cycles to account for the unique reporting on that instrument that does not count the first 10 162

cycles.

Analytic sensitivity curves were generated through logistic regression, using CT as the 165 independent variable, and ID NOW, Sofia 2, or Simplexa result (positive/negative) as the 166 dependent variable, along with 95% point-wise confidence intervals and p-values calculated by 167 the likelihood ratio test.(12) Because ID NOW and Sofia 2 require direct-swabs in clinical 168

practice, an adjustment was made to account for the VTM dilution that will not typically occur. In 169 the ID NOW study, 200 ul of VTM were transferred, representing 6.6% of the total VTM volume 170

(3 ml tube), and therefore 6.6% of total viral particles. For Sofia 2, 50 ul of VTM were 171 transferred, representing 1.6% of viral particles. Assuming direct-swabbing would transfer 100% 172 of viral particles into the assay, there would be 1/.066 = 15 times (ID NOW) and 1/.016 = 60 173 times (Sofia 2) more viral particles than in VTM studies. As PCR approximately doubles gene 174 targets each cycle, dilutions were estimated to cause a 3.9 CT shift of CTs on ID NOW, and a 175 5.9 CT shift for Sofia 2. For example, if ID NOW detected a VTM specimen of CT 25.0, we 176 added 3.9 CT for a final value of 28.9 CT for that specimen to be used in the ID NOW logistic 177 regression, as direct-swab testing should detect lower viral loads. 178 179

Step 3: For patient populations-of-interest, distributions of CTs from October 10 th , 2020 through 180

January 31 st , 2021 were queried from our institution's electronic medical record (supplemental 181 Figure S1 ). These CTs were from different instruments as, e.g., the emergency services CTs 182 derived from Simplexa S-gene CT, while outpatient CTs derived from central laboratory PCR 183

assays. The analyses in this study pertain to emergency services patients only.

Step 4: Logistic regressions from Step 2 for the different assays and specimen types were then 186 applied to the historic CT distributions for emergency services symptomatic and asymptomatic 187

patients. For example, if logistic regression predicted 50% analytic sensitivity for samples 188 positive at CT 35.0, then it was predicted the assay would detect 50% of cases of CT 35.0 in the 189 population-of-interest. This was repeated for each CT value in the distribution and total detected 190 cases were summed and divided by the total distribution count to calculate a predicted positive 191 percent agreement (pPPA). Since the emergency services CT distribution was generated by 192

Simplexa, it is a pPPA against the Simplexa. We also calculate the pPPA of the Simplexa 193 against the historic Simplexa CT distribution, which is expected to be below 100% when some 194 samples are near the LOD. This allows use of the pPPA as an index to compare the 195 performance of proposed assays with the current assay (i.e., the Simplexa). While the Simplexa positives would be expected to be the same between runs. 199 200

Step 5: Finally, estimates of missed cases per 1,000 tested were made for varying prevalences 201 as a measure that can be benchmarked against Infectious Disease Society of America (IDSA) 202

guidelines. As pPPA is not the same as diagnostic sensitivity, and since the pPPA was 203 calculated against the routine assay in use for emergency services patients (i.e., the Simplexa 204 rapid assay) that has a lower analytic sensitivity than typical reference standards, an adjustment 205 was made to account for likely additional missed cases. This was achieved by binning 206 emergency services CT-distributions into 10 bins based on the Simplexa analytic sensitivity 207

curve fit with LOD data such that the CT-bins represented equally spaced sensitivity windows 208 (i.e., windows with midpoints of 95%, 85%, etc). Then, a multiplier for each CT-value was 209 calculated as the inverse of the Simplexa analytic sensitivity for the midpoint of the relevant CT-210

window, rounded to two decimal places (i.e., 1.05, 1.18), and multiplied by 100 (i.e. 105, 118). 211

Finally, new CT distributions were created such that each original CT value was instead 212

represented by replicates according to this multiplier. This process accounts for cases likely 213 missed in routine testing and will enrich the CT-distribution with higher values. Total missed 214

cases per 1000 tested were calculated using analytic sensitivity curves against these enriched 215

CT-distributions. This was estimated for all missed cases and for cases < 33.0 CT,(13,14) 216

although the exact cutoff for infectiousness is contentious. (15) 217 218

A paired-swab study was conducted after these modeling exercises were complete. IRB 219 approval was not required as per institutional policy of clinical quality improvement projects. In 220 96 patients presenting to adult emergency services, a direct nasopharyngeal swab was 221 collected for the ID NOW and testing was performed within 1 hour, and another nasopharyngeal 222 swab was collected simultaneously in VTM and performed on the Simplexa. ID NOW positive 223 results were communicated to those performing the Simplexa assay to facilitate patient care. As 224 this was a study meant to compare ID NOW to Simplexa (the institutional standard for 225 emergency services) only discrepant specimens were sent to the central laboratory for 226 confirmation on either the Alinity or m2000.

For all clinical and laboratory testing, each assay was performed according to manufacturer's 229 EUA instructions, with the exception of the use of residual VTM samples for ID NOW (7) and 230 Sofia 2 (as described above). In all analyses, patient status (symptomatic vs asymptomatic) was 231 determined from an institutional checklist based on federal reporting guidance.(16) All statistical 232 analyses were conducted in R statistical environment (R Foundation for Statistical Computing, 233

Vienna, Austria), and dot plots were generated in GraphPad Prism 9 (GraphPad Software, San 234

Diego, USA). A bootstrap version of the univariate Kolmogorov-Smirnov test was used to 235 compare CT distributions from patients enrolled in the paired-swab study and those not enrolled 236

(10,000 bootstraps).

Results

Bias between PCR assays in this study was less than 1 CT. Simplexa showed a -0.15 bias with 241 m2000, and Alinity showed a 0.82 bias with m2000 (supplemental Figure S2 , see difference 242 plot). Analytic sensitivity curves of point-of-care assays, across CTs generated by 243 nasopharyngeal VTM specimens on our central laboratory assays, are shown in Figure 1 .

Logistic regression estimated direct-swab nasal ID NOW analytic sensitivity, fit with direct-swab 245 nasal specimen data as 95% at CT 20.1, 50% at 28.8, and 5% at 37.4. It estimated direct-swab 246

nasopharyngeal ID NOW analytic sensitivity, fit with patient VTM data, as 95% at CT 27.5, 50% Applying these logistic regression models to the emergency services symptomatic population 255 (Figure 2 , Similarly, for the asymptomatic population presenting for emergency services (Figure 3 , Table  265 2), overall pPPA for ID NOW using direct nasal specimens was estimated to be 64.5% When adjusting for cases likely missed in the routine testing that generated the historic CT-274

distributions, the number of predicted missed cases, and potentially infectious missed cases 275 with CT<33.0, per 1,000 tested were plotted by prevalence in Figure 4 . In symptomatic 276 emergency services patients at 15% SARS-CoV-2 prevalence, ID NOW direct nasal testing was 277 predicted to miss 33.8 (16.7-75.0) infected cases per 1,000. Using direct nasopharyngeal 278 specimens, ID NOW was predicted to miss 8.3 (2.6-51.8) (fit with patient VTM data) and 4.5 279

(2.3-51.6) (fit with LOD data) infected cases per 1,000 tested and Sofia 2 was predicted to miss 280 35.7 (23.6-65.9) cases. Using nasopharyngeal VTM samples, Simplexa was predicted to miss 281 4.1 (0.5-146.0) (fit with patient VTM data) and 4.8 (1.8-25.7) (fit with LOD data) cases.

In asymptomatic emergency services patients and at 3% prevalence, ID NOW direct nasal 284

testing was predicted to miss 15.0 (9.3-20.7) infected cases per 1,000. Using direct 285 nasopharyngeal specimens, ID NOW was predicted to miss 7. In the paired-swab study of 96 emergency services patients (average age 53 years), 25 291 positives (18 symptomatic and 7 asymptomatic) were identified, with nearly 100% concordance 292 between the ID NOW and Simplexa results (Table S1 ). The only discrepancy was an ID NOW 293

positive/Simplexa negative sample that was confirmed in the clinical laboratories as positive at 294

CT 34.6. One sample was excluded from analysis due to a specimen aliquoting error when 295 tested on Simplexa. The distribution of CT values detected by Simplexa ranged from 11.0 CT to 296 32.1 CT (supplemental Figure S3 , a dotplot of positives on the Simplexa, whether enrolled in the Using this approach, other data sources could be incorporated. For instance, the CT difference 326 between testing nasal versus nasopharyngeal specimens could potentially be estimated.(10) 327

Using that CT benefit, one could map the nasal specimen analytic sensitivity curve (from a 328 clinical nasal specimen study) to a predicted nasopharyngeal specimen curve. Similarly, one 329 could use this method to predict performance with specimen-pooling in different populations, 330

either based on a clinical study, LOD study, or simple CT adjustment of 2.3 cycles knowing that 331 there will be a dilution of five times the concentration of viral particles (if pooling 5 specimens). 332

Another data source is literature, when CTs of positive cases are reported.

A quality target for diagnostic sensitivity of SARS-COV-2 assays is not universally accepted. 335

However, IDSA determined an acceptable benchmark for symptomatic patients at 10-20 missed 336

cases per 1,000 tested, while >60 per 1,000 was deemed unacceptable (recommendations 5, 337 6).(25) In our modeling, ID NOW and Simplexa using nasopharyngeal specimens were not 338 expected to exceed 20 missed cases per 1,000 in symptomatic patients up to (and beyond) a 339

prevalence of 20% and in asymptomatic patients up to a prevalence of 6%). In contrast, ID 340 NOW nasal testing and Sofia 2 nasopharyngeal testing were expected to exceed 20 missed 341

cases per 1,000 tested in symptomatic patients at 8% prevalence and in asymptomatic patients 342 at 3-4% prevalence. Importantly, missed cases of CT<33.0, with presumably higher infectious 343 risk, were much lower for all assays.

It should be noted that the values in Figure 4 represent estimated total missed cases for each 346 diagnostic, and not additional missed cases in comparison to the institutional standard. Also, 347 while missed cases by the institutional standard will be lower, even the highest sensitivity 8 348 central laboratory assays will by definition miss samples with viral loads at and beyond their 349 95% LOD. It should also be mentioned that Simplexa was not estimated to detect 100% of 350 emergency services cases, even though the Simplexa was the assay that resulted the CT 351 distributions used for the modeling. This is once again because the assay is detecting cases at 352

and below the 95% LOD in routine practice and therefore is expected to be missing some 353

cases.

Finally, this modeling approach could be employed for other types of qualitative diagnostic 356 testing where there is an associated quantitative output (e.g. CT value) that acts as a surrogate 357

for the biomarker concentration and when the primary driver of sensitivity is thought to be the 358 biomarker's concentration in the specimen. This would likely apply to other infectious disease 359 testing such as influenza and RSV. 360 361

There are limitations to this study. First, to estimate the benefit of direct-swab testing compared 362

to VTM, we assumed nucleic acid doubling per PCR cycle. This is expected during the 363 exponential PCR phase, when reagents exceed template. At high CT values, this relationship 364

can degrade. Furthermore, there will be dispersion around this doubling, as can be seen in the 365 LOD study, where CT values ranged across ~7 CT when theoretically 5 doubling dilutions would 366 cover 5 CT. Second, PPAs are typically calculated against the highest sensitivity assay at an 367 institution. In our study, the emergency services CT distributions were generated by the highest 368

sensitivity rapid assay at our institution, but still with a sensitivity lower than the central 369 laboratory. The pPPAs are still valid, but should not be equated to diagnostic sensitivity. Had 370

CT-distributions of the same patients been generated by central laboratory instruments, pPPAs 371

of Figures 2 and 3 would be lower. Nevertheless, the pPPA is valuable as an index to compare 372 the relative performance of different assays in various specimen types and populations. Third, 373 estimation of total missed cases required another data manipulation step to quantify likely 374 missed cases not present in the electronic health record, thus creating additional uncertainty in 375 those results. Fourth, CTs are not specifically harmonized between instruments and therefore 376

CT distributions between different patient populations may not be directly comparable, to the 377 extent that CT values between two assays show bias. While one could consider mapping assay 378

CTs to viral load, this was not done as bias was deemed minimal and using CTs directly 379

reduced the burden of model deployment.

The impetus for this study came from our institutional need to develop a model to initially assess 382 the viability of several COVID assays, particularly those that cannot be evaluated with residual 383 specimens. Early in the pandemic we implemented the Simplexa COVID-19 assay where rapid 384 testing was critical (e.g., in emergency services), as it had a 90-minute turn-around time. As the 385 pandemic continued and the need for more rapid testing became critical, we sought to identify a 386 new assay with a shorter turn-around time but similar performance characteristics to the 387 Simplexa. The model presented here permitted an efficient evaluation of several 388 assay/specimen-type/population combinations and predicted the ID NOW using a direct 389 nasopharyngeal specimen would perform similarly to Simplexa. VTM or LOD data, as described in methods. Source of data for fitting the logistic regression is 514 listed in parentheses; predictions are for use with direct specimens in the case of ID NOW and 515

Sofia 2 but VTM in the case of Simplexa, as per package insert. Orange circles represent assay 516 result (100=positive, 0=negative), thin grey lines represent 95% confidence intervals of logistic 517 regression. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 542 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 

Warning From COVID-19 Test Providers U.S. coronavirus 432 testing could fail again, as surging demand creates new backlogs and delays

The Rockefeller Foundation. Taking Back Control A Resetting of America ' s Response to 436 Covid-19

COVID-19 Testing Scale-Up : 438 Key Issues and Considerations for Michigan Policymakers

Hospital Experiences Responding to the COVID-19 Pandemic: Results of a National 442 Pulse Survey

COVID-19 Point-of-Care Diagnostics That Satisfy 444 Global Target Product Profiles

Point of Care 446 Diagnostics in the Age of COVID-19

Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms 449 demonstrates that ID NOW performance is impaired substantially by patient and 450 specimen type

Diagnosis of 452 SARS-CoV-2 by RT-PCR Using Different Sample Sources: Review of the Literature. Ear

A 455 Comparison of Five SARS-CoV-2 Molecular Assays With Clinical Correlations

Nasal-Swab Testing Misses 458 Patients with Low SARS-CoV-2 Viral Loads

Analytic 460 Sensitivity of 3 Nucleic Acid Detection Assays in Diagnosis of SARS-CoV-2 Infection

The Likelihood Ratio, Wald, and Lagrange Multiplier Tests: An Expository Note

Viral RNA 465 load as determined by cell culture as a management tool for discharge of SARS-CoV-2 466 patients from infectious disease wards

Cycle 469 threshold values in the context of multiple rt-pcr testing for sars-cov-2. Risk Manag 470 Healthc Policy

472 SARS-CoV-2, CT-Values, and Infectivity-Conclusions to Be Drawn from Side 473 Observations Martin

HHS Laboratory Data Reporting 475 Guidance for COVID-19 Testing Under CARES

The Utility of Rapid Nucleic 478

Acid Amplification Testing to Triage Symptomatic Patients and to Screen Asymptomatic 479

Preprocedure Patients for SARS-CoV-2

Performance of Abbott ID 481 Now COVID-19 Rapid Nucleic Acid Amplification Test Using Nasopharyngeal Swabs 482 Transported in Viral Transport Media and Dry Nasal Swabs in a New York City Academic 483 Institution

Comparison of Abbott 485 ID Now and Abbott m2000 methods for the detection of SARS-CoV-2 from 486 nasopharyngeal and nasal swabs from symptomatic patients

Comparison of Four Molecular In Vitro Diagnostic 488 Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens

Direct Comparison of 491 SARS-CoV-2 Analytical Limits of Detection across Seven Molecular Assays

Rapid and sensitive 494 detection of SARS-CoV-2 RNA using the Simplexa TM COVID-19 direct assay

Clinical Evaluation 497 and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of 498 SARS-CoV-2

Comparison of 500 abbott id now, diasorin simplexa, and CDC fda emergency use authorization methods for 501 the detection of sars-cov-2 from nasopharyngeal and nasal swabs from individuals 502 diagnosed with covid-19

ID NOW, nasal (direct-swab data) 77.8% (50.2%−89.1%) 64.5% (40.8%−79.8%)

np (VTM data) 94.9% (65.8%−98.5%) 88.4% (59.8%−95.5%)

np (LOD data) 97.4 (66%−98.8%) 89.6% (57.4%−94.7%)

np (VTM data) 76.6% (56.4%−84.7%) 60.3% (45%−71.4%)

Simplexa, np (VTM data) 97.8% (2.7%−99.7%) 91.1% (6.2%−99%)

Simplexa, np (LOD data) 97.2% (83.3%−98.9%) 90.8% (75.2%−96.2%)

Abbr: pPPA (predicted positive percent agreement)

COVID prevalence in this population (%)

ID NOW, nasal (direct-swab data)

Sofia 2, np (VTM data)

np (VTM data) ID NOW, np

VTM data) Simplexa, np (LOD data)

ID NOW, nasal (direct-swab data)

Sofia 2, np (VTM data)

np (VTM data) ID NOW, np

VTM data) Simplexa, np (LOD data)

ID NOW, nasal (direct-swab data)

Sofia 2, np (VTM data)

np (VTM data) ID NOW, np

VTM data) Simplexa, np (LOD data)

Acknowledgments: We are grateful for contributions from Amy Rosendaul and the laboratory